Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RecoverPC: Relugolix vs Leuprolide in Prostate Cancer
NCT05765500Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2024
- Primary completion
- Jul 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Feb 2024; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05765500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765500.